首页|肝纤维化临床分期对抗肝纤维化治疗效果的预测价值研究

肝纤维化临床分期对抗肝纤维化治疗效果的预测价值研究

扫码查看
目的 探讨肝纤维化临床分期对抗肝纤维化治疗效果的预测价值。方法 回顾分析 78 例慢性乙型肝炎(乙肝)患者的治疗情况,所有患者均经历过肝穿刺活检,同时在 4 周内完成了血液常规、生物化学以及凝血学的测试。基于肝纤维化的各个发展阶段,将 78 例患者分为F01 组(Metavir评分介于 0~1 分,30 例)、F23 组(Metavir评分介于 2~3 分,28 例)以及F4 组(Metavir评分为 4 分,20 例)。比较三组临床资料及实验室指标,分析 6 种模式评分与肝纤维化程度的相关性,以受试者工作特征曲线(ROC曲线)分析 6 种模型(APRI、FIB-4、Forns、HB-F、APGA、Hui模型)预测慢性乙肝患者肝显著纤维化的效能。结果 三组患者的男性占比、身高和总胆固醇(TC)比较,差异并不显著(P>0。05);三组患者的年龄、体质量、血小板计数(PLT)、丙氨酸氨基转氨酶(ALT)、天冬氨酸氨基转氨酶(AST)、碱性磷酸酶(ALP)、γ-谷氨酰转移酶(GGT)、白蛋白(ALB)、总胆红素(TBIL)、凝血酶原时间(PT)、甲胎蛋白(AFP)比较,差异非常显著(P<0。05)。APRI、FIB-4、Forns、HB-F、APGA、Hui模型指数与肝纤维化的严重性呈正相关(r=0。607、0。677、0。690、0。498、0。609、0。610,P<0。05)。在 78 例慢性乙肝患者中,有 60 例(76。92%)患者的ALT<2 倍正常值上限(ULN)。结论 不管ALT≥2 倍ULN还是ALT<2 倍ULN,肝纤维化临床分期都可以准确地识别出慢性乙肝患者的明显肝纤维化和肝硬化,此外,APGA模型所包含的数据也相当容易获取,因此非常适宜于实际的医疗应用。
A study of the predictive value of clinical staging of liver fibrosis on the outcome of anti-hepatic fibrosis treatment
Objective To explore the predictive value of clinical staging of liver fibrosis on the outcome of anti-hepatic fibrosis treatment.Methods 78 patients with chronic hepatitis B(Hepatitis B)were retrospectively analyzed,all of whom underwent a liver puncture biopsy along with routine blood,biochemistry,and coagulation tests completed within 4 weeks.Based on the various stages of liver fibrosis development,78 patients were divided into group F01(Metavir score 0-1 points,30 patients),group F23(Metavir score 2-3 points,28 patients),and group F4(Metavir score 4 points,20 patients).The clinical data and laboratory indicators of the three groups were compared to analyze the correlation between the six model scores and the degree of liver fibrosis,and the efficacy of the six models(APRI,FIB-4,Forns,HB-F,APGA,and Hui models)in predicting liver significant fibrosis in patients with chronic hepatitis B was analyzed by receiver operating characteristic(ROC)curve.Results Comparison of the percentage of males,height and total cholesterol(TC)among the three groups of patients,the difference was not significant(P>0.05).Comparison of age,body mass,platelet count(PLT),alanine aminotrasferase(ALT),aspartate transaminase(AST),alkaline phosphatase(ALP),gamma-glutamyl transferase(GGT),albumin(ALB),total bilirubin(TBIL),prothrombin time(PT),alpha fetoprotein(AFP)among the three groups of patients,the difference was highly significant(P<0.05).APRI,FIB-4,Forns,HB-F,APGA,Hui model index were positively correlated with the severity of liver fibrosis(r=0.607,0.677,0.690,0.498,0.609,0.610;P<0.05).Of the 78 patients with chronic hepatitis B,60 cases(76.92%)had ALT<2 times the upper limit of normal(ULN).Conclusion Regardless of whether ALT≥2 times ULN or ALT<2 times ULN,clinical staging of liver fibrosis can accurately identify significant liver fibrosis and cirrhosis in patients with chronic hepatitis B.In addition,the data contained in the APGA model are quite easy to access,making it highly suitable for practical medical applications.

Clinical staging of liver fibrosisLiver fibrosisTherapeutic effectPredictive value

宋宇震、俞晓芳、吴昦辰

展开 >

361009 厦门市中医院

肝纤维化临床分期 肝纤维化 治疗效果 预测价值

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(24)